Conference Correspondent

Antimicrobial Stewardship Program Aims to Reduce Antimicrobial Usage in Geriatric Patients without Affecting Outcomes

Conference Correspondent - IDWeek 2018

Literature is limited in regard to evaluating antimicrobial stewardship program (ASP) outcomes in patients aged ≥65 years. Researchers performed a retrospective chart review of 461 patients (150 control and 311 intervention) to compare the rates of 30-day readmissions of patients aged ≥65 years who received ASP interventions with a control sample who received antibiotics pre-ASP.

Patients were included if they received antibiotics for pneumonia (PNA), urinary tract infection (UTI), acute bacterial skin and skin structure infection (ABSSSI), and complicated intra-abdominal infection (cIAI). Interventions consisted of de-escalation of empiric or definitive therapy, change in duration of therapy, or discontinuation of therapy. Treatment failure was defined as readmission due to reinfection or development of a new infection (eg, Clostridium difficile).

The 30-day readmission rate for all infections decreased during the intervention period (10.7% vs 3.9%; P = .004). There was a statistically significant decrease in 30-day readmissions in the PNA subgroup (9.8% vs 2.9%; P = .038), a marginally significant decrease among patients with UTI (12.5% vs 4.7%; P = .097), and no statistically significant change in the ABSSSI (5.6% vs 8.6%; P = .694) and cIAI (20.8% vs 6.7%; P = .233) subgroups. The total adjusted patient-days (APDs) were 16,267 (control) and 15,487 (intervention). Total antimicrobial expenditure during the control period was $379,643 ($23.33/APD) versus $67,721 ($4.37/APD) during the intervention period.

ASP efforts did not lead to an increased rate of 30-day readmissions due to treatment failure. Furthermore, there was a statistically significant decrease in readmission rates in the intervention group, as well as a large decrease in antimicrobial expenditure per APD.

Source: Mauro J, et al. IDWeek 2018. Abstract 246.

Related Items
Pooled Analysis of Safety Data from Phase 2 and 3 Clinical Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections
Conference Correspondent published on October 5, 2018 in IDWeek 2018
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
Conference Correspondent published on October 5, 2018 in IDWeek 2018
Health-Related Social Vulnerabilities in a Pediatric Outpatient Antimicrobial Therapy Program
Conference Correspondent published on October 5, 2018 in IDWeek 2018
The AMMO Study: Antimicrobial Management in Extracorporeal Membrane Oxygenation
Conference Correspondent published on October 5, 2018 in IDWeek 2018
Systematic Review and Network Meta-Analysis of Randomized Trials of Antibiotic Therapy for Community-Acquired Pneumonia
Conference Correspondent published on October 5, 2018 in IDWeek 2018
Last modified: October 5, 2018
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME